Search This Blog

Tuesday, July 14, 2026

Celcuity gets FDA approval for first product REVTORPYK (gedatolisib) to treat breast cancer

 

Celcuity gets FDA approval for first product REVTORPYK (gedatolisib) to treat HR+/HER2-, PIK3CA wild-type metastatic breast cancer

  • Approval covers locally advanced or metastatic breast cancer after progression on endocrine therapy.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)